Evidence map›Paper›PMID 42519339›Full record

ArticleFrontiers in immunology2026

Aluminé Lezcano, Emanuel Miculan, Geronimo Ducca, Carolina Ruera, María Luz Iribarren, Philippe Tixador, Xavier Roux, Fernando Gabriel Chirdo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aluminé LezcanoDepartamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Instituto de Estudios Inmunológicos y Fisiopatológicos - IIFP (UNLP-CONICET), Universidad Nacional de La Plata, La Plata, Argentina.
Emanuel MiculanDepartamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Instituto de Estudios Inmunológicos y Fisiopatológicos - IIFP (UNLP-CONICET), Universidad Nacional de La Plata, La Plata, Argentina.
Geronimo DuccaDepartamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Instituto de Estudios Inmunológicos y Fisiopatológicos - IIFP (UNLP-CONICET), Universidad Nacional de La Plata, La Plata, Argentina.
Carolina RueraDepartamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Instituto de Estudios Inmunológicos y Fisiopatológicos - IIFP (UNLP-CONICET), Universidad Nacional de La Plata, La Plata, Argentina.
María Luz IribarrenDepartamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Instituto de Estudios Inmunológicos y Fisiopatológicos - IIFP (UNLP-CONICET), Universidad Nacional de La Plata, La Plata, Argentina.
Philippe TixadorMicrobiology Department, Biocodex Simplified Joint-Stock Company (SAS), Compiegne, France.
Xavier RouxMicrobiology Department, Biocodex Simplified Joint-Stock Company (SAS), Compiegne, France.
Fernando Gabriel ChirdoDepartamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Instituto de Estudios Inmunológicos y Fisiopatológicos - IIFP (UNLP-CONICET), Universidad Nacional de La Plata, La Plata, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Inflammation of the small intestine can be caused by infections, immune-mediated disorders (such as celiac disease) and medications, leading to malabsorption, chronic diarrhea, and subclinical alterations including increased gut permeability and systemic inflammation. It has been suggested that probiotics can restore barrier integrity and reduce inflammation. The objective of the present study was to evaluate the effects of the probiotic yeast Methods: The mice were challenged with a single dose of p31-43 or multiple doses over a three-week period, with or without Results and discussion: Compared with mice treated with single or repeated doses of p31-43 alone, concomitant

Indexed as

EnteritisGliadinIntestine, SmallProbioticsSaccharomyces boulardiiAnimalsDisease Models, AnimalIntestinal Barrier FunctionIntestinal MucosaMaleMiceGliadincell deathintestinal inflammationprobioticsSaccharomyces boulardiismall intestinesterile inflammation

Identifiers

PMID42519339
PMCPMC13381514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.